Finance

Cancer/inflammation-focused company reports smaller loss in Q3

Published in Cancer Weekly, December 14th, 2004

EntreMed, Inc., (ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammation, reported results for the 3- and 9-month periods ending September 30, 2004.

Revenues for the third-quarter 2004 were approximately $143,000 versus $258,000 for the comparable period a year ago. The company reported a net loss for the third quarter of approximately $3.1 million, or $0.09 per share. This compares with a net loss of approximately $4.6 million, or $0.15 per share for the same period last year.

For the 9 months ending September 30, 2004, revenues were approximately $380,000 versus $1.1 million for 2003....

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2004-12-14)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry